XL880 (GSK1363089)

XL880 (GSK1363089) is a potent inhibitor of MET and VEGFR2 which play cooperative roles in promoting tumor growth and angiogenesis. MET is mutationally activated in hereditary papillary renal cell carcinoma and in some head and neck cancers, is activated or overexpressed in glioblastomas, breast carcinomas, non-small cell lung cancers, and other solid tumors, and is amplified in a subset of gastric and lung cancers. Pursuant to a product development and commercialization agreement between Exelixis and GlaxoSmithKline, Glaxo-SmithKline exercised its option to further develop and commercialize XL880.